Published online Dec 16, 2016. doi: 10.4253/wjge.v8.i20.723
Peer-review started: April 5, 2016
First decision: June 12, 2016
Revised: August 16, 2016
Accepted: September 21, 2016
Article in press: September 22, 2016
Published online: December 16, 2016
Processing time: 259 Days and 2.4 Hours
Endoscopy is a keystone in the management of patients with inflammatory bowel disease (IBD). It is the fundamental diagnostic tool for IBD, and can help discern between ulcerative colitis and Crohn’s disease. Endoscopic assessment provides an objective end point in clinical trials, and identifies patients in clinical practice who may benefit from treatment escalation and may assist risk stratification in patients seeking to discontinue therapy. Recent advances in endoscopic assessment of patients with IBD include video capsule endoscopy, and chromoendoscopy. Technological advances enable improved visualization and focused biopsy sampling. Endoscopic resection and close surveillance of dysplastic lesions where feasible is recommended instead of prophylactic colectomy.
Core tip: Ileo-colonoscopy remains the most important test in the diagnosis and monitoring of inflammatory bowel disease (IBD). Video capsule endoscopy shows very high sensitivity for small bowel mucosal lesions not accessible to conventional flexible endoscopes. Both techniques facilitate monitoring of response to treatment. Endoscopic activity indices are important for monitoring treatment response and can help identify patients who may benefit from treatment escalation. Colorectal cancer surveillance in patients with IBD is shifting from high frequency random biopsies, to that of high quality visual inspection and targeted biopsies of suspected dysplasia, enabled by technological advances including chromoendoscopy and high-definition endoscopes.